Haemonetics Corporation (NYSE: HAE) last traded at $122.06, up 2.84% on the session. The quote above updates while this page is open; the figures below are drawn from Haemonetics Corporation’s own filings and are restated only when a new one is published.
Haemonetics Corporation trades on NYSE under the ticker HAE. Its market capitalisation is $5.55 billion.
Valuation measures for Haemonetics Corporation, derived from the latest quote and its most recent SEC filing.
| Market cap | $5.55B |
|---|---|
| Enterprise value | $6.86B |
| P/E ratio | 58.97 |
| Price / sales | 4.11 |
| Price / book | 6.63 |
| Beta | -0.06 |
Trailing-twelve-month figures tagged in Haemonetics Corporation's XBRL filings with the SEC.
| Revenue (TTM) | $1.35B |
|---|---|
| Net income (TTM) | $96.29M |
| EPS (TTM) | $2.07 |
| Gross margin | 59.03% |
| Operating margin | 11.86% |
| Return on equity | 11.50% |
| Cash | $223.38M |
Range and volume for HAE over the past 52 weeks.
| 52-week high | $122.24 |
|---|---|
| 52-week low | $48.55 |
| Volume | 895.0K |
| Average volume | 730.7K |
| Previous close | $118.69 |
Invest a chosen dollar amount in Haemonetics Corporation with fractional shares.
Start investingCreate an account
Investing involves risk, including possible loss of principal. Nothing here is investment advice or a recommendation to buy or sell HAE.
A dash means FurlPay does not have that figure, not that it is zero. Nothing on this page is investment advice or a recommendation to buy or sell any security. Figures are provided for information only and may be delayed or restated.